[Double-blind trial of tiapride versus placebo in patients with sub-perennial idiopathic headache].
25 patients with sub-perennial idiopathic headache were given tiapride or a placebo in a double-blind controlled trial, over thirteen weeks. Tiapride was given orally in a dosage of 300 mg per day. Blood was drawn in 10 patients and 10 healthy controls for blood prolactin determination. No significant side-effects were recorded during the trial. Statistical analysis of the results is reported. Tiapride proved effective in reducing the frequency of headache (in 65% of patients), with an improvement rate which was statistically significant in comparison to the placebo. The drug seems to improve the headache index itself, although the difference was not statistically significant; however, the number of patients was small.
D000328:Adult; D001549:Benzamides / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*
D001549:Benzamides; D010919:Placebos; D013976:Tiapamil Hydrochloride
Etude en double aveugle tiapride contre placebo chez des patients souffrant de céphalées essentielles subcontinues.